This study examines the impact of Respiratory Syncytial Virus (RSV) on people of all ages, from infants to the elderly. It uses hospital records collected between January 2018 and December 2024 to understand: * How often does RSV occur * Who is most at risk * The long-term and financial effects of RSV
This study is designed to analyze the impact of Respiratory Syncytial Virus (RSV) across different age groups. It focuses on how often RSV occurs, who is most at risk, and its long-term and financial effects. The study uses existing hospital records from SEHA facilities between January 2018 and December 2024. This is a retrospective observational study, meaning no new tests or treatments are given. Researchers look at medical records from past patients who were diagnosed with RSV. Anonymized data is collected from SEHA's Electronic Medical Records (EMR) and laboratory systems. Only patients with confirmed RSV infections are included.
Study Type
OBSERVATIONAL
Enrollment
1,500
Sheikh Khalifa Medical City (Abu Dhabi Health Research Centre), SEHA
Abu Dhabi, United Arab Emirates
Burden of RSV Infection Across All Age Groups
Measurement of the incidence of confirmed RSV infections in patients of all ages using SEHA hospital data from January 2018 to December 2024.
Time frame: January 2018 - December 2024
Burden of RSV Infection Across All Age Groups
Measurement of the prevalence of confirmed RSV infections in patients of all ages using SEHA hospital data from January 2018 to December 2024.
Time frame: January 2018 - December 2024
Identification of Risk Factors for Severe RSV Infection
Analysis of clinical, demographic, and comorbidity data to identify key risk factors associated with severe RSV infection outcomes.
Time frame: January 2018 - December 2024
Proportion of Hospital Admissions Due to RSV
Evaluation of the percentage of total hospital admissions attributed to RSV infections.
Time frame: January 2018 - December 2024
ICU Admission Rates for RSV-Infected Patients
Measurement of the proportion of RSV patients requiring ICU care.
Time frame: January 2018 - December 2024
Financial Burden of RSV Infection
Assessment of direct medical costs associated with RSV hospitalization and ICU care.
Time frame: January 2018 - December 2024
Incidence of Recurrent Wheezing and Asthma Diagnosis Following RSV Infection
Evaluation of long-term respiratory complications, specifically: 1. Clinically diagnosed asthma using standardized clinical criteria (e.g., based on ICD-10 codes or physician diagnosis recorded in medical records) 2. Recurrent wheezing episodes, defined as ≥3 wheezing episodes confirmed by clinical examination or parent report within 12 months post-infection, assessed via structured caregiver questionnaires and medical record review.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Up to 12 months post-infection
RSV-Associated Mortality Rates
Analysis of death rates among RSV-positive patients, including 30-day mortality post-admission.
Time frame: January 2018 - December 2024
Long-Term Respiratory Outcomes Following RSV Infection
Evaluation of post-RSV respiratory complications such as asthma and recurrent wheezing.
Time frame: Up to 12 months post-infection